Skip to main content

Advertisement

Table 2 Patient outcomes and complications

From: Physiological predictors of survival during high-frequency oscillatory ventilation inadults with acute respiratory distress syndrome

Variable  
Airleak  
   Air Leak before HFOV 22/102 (21.6 %)
   Persistent air Leak during HFOV 5/22 (22.7 %)
   New air leak during HFOV 2/80 (2.5 %)
Co-treatment (Some patients received more than one co-treatment)  
   Nitric oxide 21/102 (20.6%)
   MARS 1/102 (0.98%)
   Steroids 19/102 (18.6%)
   Prone position 20/102 (19.6%)
   rhAPC 3/102 (2.9%)
   None 56/102 (54.9%)
Mortality  
   Post HFOV 49/102 (48%)
   ICU discharge 62/102 (60.8%)
   30-day 57/102 (55.9%)
Cause of death at 30-days  
   Withdrawal of treatment 22/57 (38.6%)
   >2 organ failure 20/57 (35.1%)
   Cardiac arrhythmia 6/57 (10.5%)
   Refractory hypoxia 4/57 (7%)
   Sepsis 3/57 (5.3%)
   Profound hypotension 2/57 (3.5%)
  1. HFOV, high-frequency oscillatory ventilation; MARS, Molecular AdsorbentsRecirculation System; rhAPC, recombinant human Activated Protein C (Drotrecoginalfa activated, Xigris).